The concern of generic competition has consistently loomed over copyright’s famous drug, Viagra, raising questions about the prospects of similar drug stakes. While initial periods saw impressive gains, the patent lapse has opened the way for cheaper copies, possibly reducing earnings and creating a real danger for investors looking for safe yiel